Neuralstem Presents ALS Trial Results at American Academy of Neurology Annual Meeting

Eleven ALS patients have been treated with Neuralstem’s stem cell therapy since the Phase I trial launched in January 2010, with seven more patients expected to undergo treatment before the completion of the safety trial. Study updates will be presented at the annual gathering of neurologists and will include the use of electrical impedance myography (EIM) to assess muscle changes in trial participants. The Neuralstem trial is the first ALS therapeutic clinical trial study to incorporate EIM, recently recognized as a breakthrough technology read more here. for monitoring ALS disease progression.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail